IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ITP IT Tech Packaging Inc

Trading 08-25 14:01:41 EDT

0.1833

+0.0043

+2.40%

High0.1870	Low0.1750	Vol364.11K
Open0.1765	D1 Closing0.1790	Amplitude6.70%
Mkt Cap3.11M	Tradable Cap3.01M	Total Shares16.97M
T/O66.44K	T/O Rate2.22%	Tradable Shares16.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ITP","market":"US","secType":"STK","nameCN":"IT Tech Packaging Inc","latestPrice":0.1833,"timestamp":1787678857053,"preClose":0.179,"halted":0,"volume":364105,"delay":0,"changeRate":0.024022346368715076,"floatShares":16423703,"shares":16965420,"eps":-0.861876,"marketStatus":"Trading","change":0.0043,"latestTime":"08-25 14:01:41 EDT","open":0.1765,"high":0.187,"low":0.175,"amount":66441.22136995,"amplitude":0.067039,"askPrice":0.1917,"askSize":15000,"bidPrice":0.1756,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-0.861876,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":0.179,"preHourTrading":{"tag":"盘前","latestPrice":0.1789,"preClose":0.179,"latestTime":"09:29 EDT","volume":2923,"amount":517.91628565,"timestamp":1787664576740,"change":-0.0001,"changeRate":-0.000559,"amplitude":0.019553},"postHourTrading":{"tag":"盘后","latestPrice":0.173,"preClose":0.179,"latestTime":"19:59 EDT","volume":751,"amount":130.7368,"timestamp":1787615947430,"change":-0.006,"changeRate":-0.03352,"amplitude":0.03352},"volumeRatio":6.196453,"impliedVol":1.4182,"impliedVolPercentile":0.4183},"requestUrl":"/m/hq/s/ITP","defaultTab":"news","newsList":[{"id":"2661695272","title":"Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2661695272","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661695272?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:32","pubTimestamp":1787581920,"startTime":"0","endTime":"0","summary":"BEIJING, Aug. 24, 2026  -- InnoCare Pharma , a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026.InnoCare delivered robust revenue growth and strengthened profitability in the first half of 2026, driven by strong commercial execution and global business development collaborations. In the first half of 2026, the Company's revenue grew by 55.5% year-on-year to RMB 1.1 billion, and profit reached RMB 239.7 million, a turnaround from a loss in the same period last year. These results reflect the successful implementation of the Company's strategy driven by innovation, commercialization and globalization.In the first half of 2026, InnoCare continued to accelerate innovation, achieving a series of key milestones.-- 1 NDA approval: Orelabrutinib was approved in Australia.-- 2 NDA acceptances: The NDA applications for orelabrutinib in primary. immune thrombocytopenia  a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","MTD","IE00B5TLWC47.USD","IND","BK4588","CR","BK4077","ORR","ITP","SLE","PFS","BK4195","IE00BFXG0V08.USD","09969","BK4585","LU2413666426.HKD","BK4211","BK1574","BK4548","BK4161","BK4121","BK4199","LU1093756325.SGD","LU1721428933.USD","BK1161","BK4567","IE00BYQQ9H92.USD","LU0347712357.USD","LU2211817866.USD","LU1093756168.USD","LU2413666699.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661027963","title":"Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2661027963","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661027963?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Aug.  24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investm","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349677/0/en/bionano-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658436409","title":"It Tech Packaging Tunda Rilis Laporan Keuangan Kuartal II 2026, Ajukan Pemberitahuan Keterlambatan 10-Q","url":"https://stock-news.laohu8.com/highlight/detail?id=2658436409","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658436409?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:20","pubTimestamp":1786479648,"startTime":"0","endTime":"0","summary":"IT Tech Packaging tunda rilis laporan keuangan kuartal II 2026, ajukan pemberitahuan keterlambatan 10-QIT Tech Packaging mengajukan pemberitahuan keterlambatan untuk laporan kuartalan Form 10-Q period","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDLc95TJX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"It Tech Packaging Tunda Rilis Laporan Keuangan Kuartal II 2026, Ajukan Pemberitahuan Keterlambatan 10-Q","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657825638","title":"Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657825638","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657825638?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014000,"startTime":"0","endTime":"0","summary":"-- At the EULAR 2026 Congress in June, the Company presented. promising initial single target dose data, which demonstrated the. potential for immune reset in a refractory and heterogeneous SLE. population. CLN-978 also improved lab markers of disease activity. and demonstrated deep, dose-dependent B cell depletion in. peripheral blood as well as dose-dependent recovery with a. -- In Q4 2026, the Company plans to share initial multi-dose regimen. data. The Company also plans to begin Phase 2 expansion in early. 2027 in patients with SLE and in patients with lupus nephritis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP","CGEM","BK4077","BK4139","RA","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655871907","title":"Agios Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655871907","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655871907?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:30","pubTimestamp":1785407400,"startTime":"0","endTime":"0","summary":"Mitapivat (PYRUKYND and AQVESME) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025Strong U.S. commercial launch o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335866/31990/en/Agios-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","IE00BKVL7J92.USD","LU0058720904.USD","LU2404859741.USD","LU0432979614.USD","LU1791710400.SGD","LU2746668974.SGD","IE00BHPRN162.USD","LU2237443895.HKD","IHI","LU1363072403.SGD","LU2362541273.HKD","LU0528227936.USD","BK4504","BK4199","LU2237443978.SGD","BK4006","LU2506952170.USD","GCC","BK4566","IE00BFXG1179.USD","CMC","LU2362540622.SGD","LU2404859667.USD","ITP","BK4156","LU0950375773.USD","SYK","LU0114720955.EUR","LU0971096721.USD","LU0170899867.USD","IE00B1BXHZ80.USD","LU0289739699.SGD","LU2237443622.USD","LU2506951958.HKD","IE00BZ1G4Q59.USD","LU0882574139.USD","LU2468319806.SGD","LU2237443549.SGD","LU0690374615.EUR","LU0882574055.USD","GB00B4QBRK32.GBP","LU2237443465.HKD","LU0267386448.USD","LU2324357040.USD","BK4082","LU2089984988.USD","LU2237443382.USD","LU0823417653.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651441085","title":"Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins","url":"https://stock-news.laohu8.com/highlight/detail?id=2651441085","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651441085?lang=en_us&edition=fundamental","pubTime":"2026-07-16 20:00","pubTimestamp":1784203200,"startTime":"0","endTime":"0","summary":"One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patient","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/16/3328383/0/en/Grifols-Doses-First-Patients-in-Two-Phase-3-Trials-to-Expand-Indications-of-its-Flagship-Immunoglobulins.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRFS","BK4006","BK4218","KBWY","PK","SID","BK4196","ITP","BK4139","AMS","PID","BK4199","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645818418","title":"Press Release: Bionano Announces Hiring of Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2645818418","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645818418?lang=en_us&edition=fundamental","pubTime":"2026-06-24 20:30","pubTimestamp":1782304200,"startTime":"0","endTime":"0","summary":"collaborative studies to bring OGM into routine use,\" said Dr. Alexander. Hoischen, PhD, Professor of Genomic Technologies at Radboud University. Medical Center, The Netherlands. \"Having Alex Hastie back means a great. deal to the OGM community. With his in-depth understanding of the. technology, he will help guide robustness and scalability, and I am. excited to expand our collaboration for research use of Bionano's. technology from ultra-high molecular weight DNA isolation to OGM,-- \"I am delighted to see Alex Hastie return to Bionano,\" said Dr. Ying Zou,MD, PhD, FACMG, Director of the Cancer Genomics Lab at Johns Hopkins. School of Medicine. \"His deep expertise in OGM technology and proven. track record in advancing genomic research make this an exciting. development for the field. I look forward to strengthening our. collaboration to unlock new insights into cancer biology and expand the. applications of OGM across both hematologic and solid tumor. -- Dr. Rashmi Kanagal-Shamanna, M","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4199","BK4121","ITP","BK4604","03160","BNGO","BK4575","BK4585","TM","BK4588","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642282351","title":"Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2642282351","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642282351?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179200,"startTime":"0","endTime":"0","summary":"Findings from 13 different studies analyzing 730 subjects to date in 2026 across multiple geographies underscore utility of OGM in key research areas including infertility, recurrent pregnancy loss, p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310421/0/en/Bionano-Announces-Multiple-Publications-in-2026-Describing-Unique-Utility-of-OGM-in-Studies-of-Reproductive-Health-and-Prenatal-Genetic-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642067289","title":"Climb Bio Reports Encouraging Early Budoprutug ITP Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2642067289","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642067289?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:30","pubTimestamp":1781177425,"startTime":"0","endTime":"0","summary":"Climb Bio ( ($CLYM) ) has shared an update. On June 11, 2026, Climb Bio, Inc. reported initial data from the ongoing Phase 1b portion of its Phase ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/climb-bio-reports-encouraging-early-budoprutug-itp-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/climb-bio-reports-encouraging-early-budoprutug-itp-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ITP","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642728928","title":"Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642728928","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642728928?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175600,"startTime":"0","endTime":"0","summary":"Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310326/0/en/Climb-Bio-Announces-Initial-Phase-1b-Data-Demonstrating-On-Target-Clinical-Activity-for-Budoprutug-in-Immune-Thrombocytopenia-at-EHA-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4199","ITP","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442360","title":"Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442360","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642442360?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:30","pubTimestamp":1781091000,"startTime":"0","endTime":"0","summary":"CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA mul","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309602/0/en/Cullinan-Therapeutics-Shares-New-Clinical-Data-Across-Its-Portfolio-of-T-Cell-Engager-Programs-Targeting-CD19-and-BCMA-in-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","IE00B19Z4B17.USD","LU2065731478.USD","CRS","IE00B7SZL793.SGD","BK4006","BK4187","IE0031619046.USD","IE00B66KJ199.SGD","BK4077","ITP","RA","BK4139","LU0963586101.USD","SLE","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640975548","title":"argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640975548","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640975548?lang=en_us&edition=fundamental","pubTime":"2026-06-03 13:00","pubTimestamp":1780462800,"startTime":"0","endTime":"0","summary":"ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren’s disease indicate maintenance of response following s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3305765/0/en/argenx-Presents-New-Efgartigimod-Data-Showing-Long-Term-Sustained-Patient-Benefit-in-Myositis-and-Sjogren-s-Disease-at-EULAR-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0994945656.USD","DM","LU1066051811.HKD","LU0426417589.USD","LU1116320737.USD","LU1228905037.USD","SG9999001440.SGD","LU1043141123.HKD","IE000M9KFDE8.USD","LU0661504455.SGD","LU1066051498.USD","HK0000914686.HKD","PM","ITP","BK4563","LU0426412945.USD","LU1066051225.USD","BK4566","LU0265550946.USD","SG9999011175.SGD","LU1228905540.USD","SG9999003800.SGD","LU1043141396.HKD","LU1116320901.HKD","LU2404859667.USD","BK4585","BK4139","BK4161","LU0738911758.USD","BK4588","LU1121112475.USD","LU1914381329.SGD","LU0265550359.USD","LU0545562505.USD","GB00B4LPDJ14.GBP","LU0949170772.SGD","LU1506573853.SGD","LU2381873111.SGD","LU1066053197.SGD","BK4546","HK0000914660.USD","IMNM","BK4199","BK4075","LU0314106906.USD","LU2404859741.USD","LU0690374961.EUR","GB00B4QBRK32.GBP","LU0690374615.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640371149","title":"Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib","url":"https://stock-news.laohu8.com/highlight/detail?id=2640371149","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640371149?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:00","pubTimestamp":1780304400,"startTime":"0","endTime":"0","summary":"Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios’ rare hematology portfolio with expansion into immune thrombocytopenia, unlo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304100/31990/en/Agios-Enters-Exclusive-Global-License-Agreement-with-Oscotec-to-Develop-and-Commercialize-Next-Generation-SYK-Inhibitor-Cevidoplenib.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2506952097.USD","LU2237443465.HKD","LU0950375773.USD","LU0149725797.USD","BK4006","LU2237443978.SGD","LU0289739699.SGD","LU2404859741.USD","LU2237443622.USD","IE00B1BXHZ80.USD","LU0114720955.EUR","BK4566","LU2089984988.USD","SYK","BK4199","LU2506951875.HKD","LU2506952170.USD","LU2746668974.SGD","LU0058720904.USD","LU1791710400.SGD","LU0170899867.USD","LU0690374961.EUR","LU2362541513.USD","LU0267386448.USD","GB00B4QBRK32.GBP","LU2237443382.USD","LU2468319806.SGD","LU1791710582.SGD","BK4585","IE00BFXG1179.USD","LU2362541273.HKD","LU2324357040.USD","LU2237443895.HKD","LU0882574055.USD","LU0823417737.USD","CMC","BK4504","LU0882574139.USD","LU1983299246.USD","ITP","LU0528227936.USD","LU0823417653.USD","LU0971096721.USD","LU2404859667.USD","LU2506951958.HKD","BK4588","LU2746668461.USD","IE00BZ1G4Q59.USD","GB00B4LPDJ14.GBP","IE00BHPRN162.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639490386","title":"InnoCare Pharma Gets Acceptance for ITP New Drug Application; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639490386","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639490386?lang=en_us&edition=fundamental","pubTime":"2026-05-29 13:38","pubTimestamp":1780033123,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SHA:688428, HKG:9969) said China's drug regulator accepted the new drug application for orelabrutinib for treating primary immune thrombocytopenia (ITP), according to a Friday filing with the Shanghai bourse.Shares of the drugmaker rose 3% in recent trade on the Hong Kong bourse.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK1574","09969","BK4199","ITP","688428","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638369844","title":"Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures","url":"https://stock-news.laohu8.com/highlight/detail?id=2638369844","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638369844?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  28, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the \"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302749/0/en/Bionano-Announces-Full-Retirement-of-Outstanding-Senior-Secured-Convertible-Debentures.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638665093","title":"InnoCare’s ITP Drug Filing for Orelabrutinib Accepted by China Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2638665093","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638665093?lang=en_us&edition=fundamental","pubTime":"2026-05-28 16:40","pubTimestamp":1779957628,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Ltd. ( ($HK:9969) ) just unveiled an announcement. InnoCare Pharma said China’s Center for Drug Evaluation has accepted its new dru...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innocares-itp-drug-filing-for-orelabrutinib-accepted-by-china-regulator?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innocares-itp-drug-filing-for-orelabrutinib-accepted-by-china-regulator?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514311","title":"Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514311","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514311?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  26, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) d","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3301017/0/en/Bionano-Announces-Largest-OGM-Study-of-T-Cell-Acute-Lymphoblastic-Leukemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","BK4179","ITP","NGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638516292","title":"Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638516292","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638516292?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:00","pubTimestamp":1779793200,"startTime":"0","endTime":"0","summary":"WELLESLEY HILLS, Mass., May  26, 2026  (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300946/0/en/Climb-Bio-to-Present-on-CLYM116-and-Budoprutug-Programs-at-European-Renal-Association-ERA-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","EPV","BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637821452","title":"US$800 million commitment achieved by FAST-P initiative Green Investments Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2637821452","media":"Lin Daoyi","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637821452?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:50","pubTimestamp":1779223822,"startTime":"0","endTime":"0","summary":"GIP has achieved its second close, obtaining a cumulative total of US$800 million in commitments.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/news/sustainability/us800-million-commitment-achieved-fast-p-initiative-green-investments?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/sustainability/us800-million-commitment-achieved-fast-p-initiative-green-investments?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["BK4567","ITP","LU0543330483.HKD","LU0878004406.USD","LU0955623706.USD","D05.SI","LU0096374516.USD","LU0488056044.USD","SG9999004360.SGD","SG9999002679.SGD","LU0672654166.SGD","LU1497734951.SGD","SG9999003826.SGD","FAST","BK4585","IE00BYQQ9H92.USD","LU0577902454.USD","SG9999001226.SGD","LU0823038988.USD","LU0823039010.USD","SG9999002620.SGD","SGXZ27511609.SGD","LU0011963245.USD","LU2506952097.USD","LU0950375773.USD","LU2506952170.USD","LU1282649067.USD","SGXZ43160589.SGD","LU0648948544.HKD","LU0261947096.USD","LU0261945553.USD","IE00BFXG0V08.USD","LU1522347837.USD","LU2506951875.HKD","LU0577902298.EUR","LU0532188223.SGD","SG9999013486.USD","LU0831093199.SGD","SG9999013460.SGD","LU2152927971.USD","LU0577902611.USD","SG9999002406.SGD","SG9999014302.SGD","LU2257852520.SGD","LU0441854154.USD","LU2238330802.EUR","LU0762540952.USD","SG9999002562.SGD","LU0048573645.USD","IE00BKZH1Z71.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635173719","title":"Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635173719","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635173719?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:00","pubTimestamp":1778756400,"startTime":"0","endTime":"0","summary":"WELLESLEY HILLS, Mass., May  14, 2026  (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294750/0/en/Climb-Bio-to-Present-New-Budoprutug-Clinical-Data-at-European-Hematology-Association-EHA-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","ITP","BK4199","EPV","BK4077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.itpackaging.cn","stockEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.0401},{"period":"3month","weight":-0.0706},{"period":"6month","weight":-0.1285},{"period":"1year","weight":-0.109},{"period":"ytd","weight":-0.1815}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.1831},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"IT Tech Packaging, Inc., together with its subsidiaries, engages in the production and distribution of paper products in the People's Republic of China. The company operates through three segments: Dongfang Paper, Tengsheng Paper, and Baoding Shengde. It offers corrugating medium papers to companies making corrugating cardboards; and offset printing papers to printing companies. The company also provides tissue paper products, including toilet papers, boxed and soft-packed tissues, handkerchief tissues, and paper napkins, as well as bathroom and kitchen paper towels under the Dongfang Paper brand. In addition, it produces and sells non-medical single-use face masks, and medical face masks. The company was formerly known as Orient Paper, Inc. and changed its name to IT Tech Packaging, Inc. in August 2018. The company is headquartered in Baoding, the People's' Republic of China.","yearOnYearQuotes":[{"month":1,"riseRate":0.411765,"avgChangeRate":0.000296},{"month":2,"riseRate":0.352941,"avgChangeRate":-0.00011},{"month":3,"riseRate":0.176471,"avgChangeRate":-0.025315},{"month":4,"riseRate":0.352941,"avgChangeRate":0.041526},{"month":5,"riseRate":0.294118,"avgChangeRate":-0.113195},{"month":6,"riseRate":0.294118,"avgChangeRate":-0.038708},{"month":7,"riseRate":0.4375,"avgChangeRate":-0.043332},{"month":8,"riseRate":0.176471,"avgChangeRate":-0.070666},{"month":9,"riseRate":0.4375,"avgChangeRate":0.011462},{"month":10,"riseRate":0.375,"avgChangeRate":0.03598},{"month":11,"riseRate":0.375,"avgChangeRate":0.097377},{"month":12,"riseRate":0.125,"avgChangeRate":0.001262}],"exchange":"AMEX","name":"IT Tech Packaging Inc","nameEN":"IT Tech Packaging Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IT Tech Packaging Inc,ITP,IT Tech Packaging Inc股票,IT Tech Packaging Inc股票老虎,IT Tech Packaging Inc股票老虎国际,IT Tech Packaging Inc行情,IT Tech Packaging Inc股票行情,IT Tech Packaging Inc股价,IT Tech Packaging Inc股市,IT Tech Packaging Inc股票价格,IT Tech Packaging Inc股票交易,IT Tech Packaging Inc股票购买,IT Tech Packaging Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction